Skip to main content

Table 2 Effects of AREDS supplements on various combinations of CFH and ARMS2 genotypes

From: Bringing the age-related macular degeneration high-risk allele age-related maculopathy susceptibility 2 into focus with stem cell technology

Author Patient information Genotype AREDS supplement Outcome measure Result Authors’ view with respect to genotyping utility
Awh et al. 2015 [21] 989 white patients with category 3 or 4 AMD 0 or 1 CFH risk alleles and no ARMS2 risk alleles Components of the AREDS formulation Seven-year treatment-specific progression rates Placebo,22.6%;with antioxidants,9.17% (P = 0.033) Support
0 or 1 CFH risk alleles and 1 or 2 ARMS2 risk alleles Placebo, 43.3%; zinc, 25.2% (P = 0.020); AREDS formulation (AF), 27.3% (P = 0.011)
2 CFH risk alleles and no ARMS2 risk alleles Placebo, 17.0%; zinc, 43.2% (P = 0.023); AF, 40.2% (P = 0.039)
2 CFH risk alleles and 1 or 2 ARMS2 risk alleles No treatment was better than placebo (48.4%)
Lee et al. 2008 [23] 876 participants at high risk for developing advanced AMD CFH TT Antioxidants + zinc,
Antioxidants,
Zinc
Progression from high risk to advanced AMD There was a nominally statistically significant interaction between AREDS supplements and the CFH Y402H genotype, and no significant treatment interactions were observed with ARMS2 Reject
TC
CC
ARMS2 GG
TG
TT
Chew et al. 2014 [24] 1237 genotyped AREDS participants of Caucasian ethnicity who were at risk of developing late AMD CFH/ARMS2 = xy, where x = CFH risk group, and y = ARMS2 risk alleles Placebo, antioxidants (vitamins C, E, beta-carotene), zinc with copper, or a combination of antioxidants, zinc, and copper Progression to late AMD No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements Reject
00
01
02
10
11
12
20
21
22
Smailhodzic et al. 2014 [25] 72 patients with various stages of AMD CFH TT A daily supplement of 50 mg zinc sulfate and 1 mg cupric sulfate for 3 months The effect of zinc on complement activation in vitro There was no significant association between changes in complement catabolism and CFH and ARMS2 genotypes, but AMD progression was slowed Reject
TC
CC
ARMS2 GG
TG
TT